Inovio's pan-covid-19 vaccine candidate (ino-4802) induces broad immunity against major viral variants in preclinical studies

Plymouth meeting, pa., may 12, 2021 /prnewswire/ -- inovio (nasdaq:ino), a biotechnology company focused on bringing to market precisely designed dna medicines to treat and protect people from infectious diseases, cancer, and hpv-associated diseases, today announced that its next-generation pan-covid-19 vaccine candidate, ino-4802, induced potent neutralizing antibodies and t cell responses against the original wuhan strain as well as against b.1.1.7 (uk variant), b.1.351 (south african variant) and p.1.
INO Ratings Summary
INO Quant Ranking